Increasing the impact of cardiological treatments. How best to reduce deaths

European Heart Journal

Volumn 20, Issue 19, 1999, Pages 1386-1392

  Capewell, S ^a   Pell, J P ^a   Morrison, C ^a   McMurray, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Audit; Cardiology; Coronary heart disease; Mortality; Treatment

Indexed keywords

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; HEALTH CARE UTILIZATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PRIORITY JOURNAL; SECONDARY PREVENTION; UNITED KINGDOM;

COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; SCOTLAND; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0032858124     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1631     Document Type: Article

References (34)

1. British Heart Foundation. Coronary Disease Statistics. London: British Heart Foundation, 1998.
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2, Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
3. Altman R, Carreras L, Diaz R et al. Collaborative overview of randomised trials of antiplatelet therapy-1 Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
4. Appleby P, Baigent C, Collins R et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
5. Garg R, Yusuf S. Overview of randomized trails of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6.
6. Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
7. Lau J, Antman EM, Jiminez-Silva J et al. Cumulative metaanalysis of therapeutic trials for myocardial infarction. N Eng J Med 1992; 327: 248-54.
8. Collins R, Baigent C, Peto R. Benefit of Heparin plus Aspirin versus aspirin alone in unstable angina. JAMA 1996; 276: 1873.
9. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70.
10. [9a] Pocock SJ, Henderson RA, Rickards AF et al. Meta analysis of randomized trials comparing coronary angioplasty with bypass-surgery. Lancet 1995; 346: 1184-9.
11. Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of beta blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997; 29: 229-36.
12. Teasdale S. The future of clinical audit: learning to work together. Br Med J 1996; 313: 574-5.
13. Capewell S, Gailey F, Fisher A, Parker S, McDonald I, Padfield PL. Audit of myocardial infarction management in South East Scotland. H Bulletin 1997; 55: 399-407.
14. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-82.
15. French JK, Williams BF, Hart HH et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J 1996; 312: 1637-41.
16. Bowker TJ, Clayton TC, Ingham J et al. A British Cardiac Society Survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
17. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. Br Med J 1991; 302: 91-2.
18. Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. Br Med J 1994; 309: 1268-9.
19. McCallum AK, Whincup PH, Morris RW, Thomson A, Walker M, Ebrahim S. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? Br J Gen Pract 1997; 47: 417-21.
20. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart-failure. Br Heart J 1994; 71: 584-7.
21. Hillis GS, Trent RJ, Winton P, Macleod AM, Jennings KP. Angiotensin-Converting-Enzyme inhibitors in the management of cardiac-failure - are we ignoring the evidence. Monthly J Ass Phys 1996; 89: 145-50.
22. Capewell S, Morrison C, McMurray J. Contribution of modern cardiovascular treatment to the decline in coronary heart disease mortality in Scotland between 1975 and 1995. Heart 1999; 81: 380-7.
23. Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. Br Med J 1990; 300: 981-3.
24. Public Health Policy Unit, Scottish Office Dept of Health. Coronary Heart Disease in Scotland: Report of a Policy Review. London: HMSO.
25. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics 1994; 3: 95-104.
26. Robinson MB, Thompson E, Black NA. Evaluation of the effectiveness of guidelines, audit and feedback: improving the use of intravenous thrombolysis in patients with suspected acute myocardial infarction. Int J Quality in H Care 1996; 3: 211-22.
27. Currie P, Gray SM, Shaw TRD, Starkey IR. Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. Scot Med J 1994; 39: 120-2.
28. Weston CFM, Penny WJ, Julian DG. Guidelines for the early management of patients with myocardial infarction. Br Med J 1994; 308: 767-71.
29. Thompson DR, Bowman GS, Kitson AL, De Bono DP, Hopkins A. Cardiac rehabilitation in the United Kingdom: guidelines and audit standards. Heart 1996; 75: 89-93.
30. Rihal CS, Yusuf S. Chronic coronary artery disease: drugs, angioplasty or surgery? Br Med J 1996; 312: 265-6.
31. Ioannidis JPA, Lau J. The impact of high risk patients on the population risk and on the population tretment effect. J Clin Epidemiol 1997; 50: 1089-98.
32. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. Br Med J 1995; 311: 793-6.
33. Mullen PD. Compliance becomes concordance. Br Med J 1997; 314: 691-2.
34. Hunink MGM, Goldman L, Tosteson ANA et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. J Am Med Ass 1997; 277: 535-42.